ESMO 2023 | KEYNOTE-585: perioperative pembrolizumab in stomach cancers

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the results of the global, randomized, double-blind, placebo-controlled KEYNOTE-585 study (NCT03221426) attempting to increase survival outcomes of patients with stomach cancer with perioperative pembrolizumab. Whilst there was some evidence of efficacy in the statistically significant primary endpoint (pathological complete response rate), event-free survival (EFS) was not significantly improved, meaning that it is now necessary to assess effects with other checkpoint inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.